What causes shock in dengue?
Severe dengue occurs as a result of secondary infection with a different virus serotype. Increased vascular permeability, together with myocardial dysfunction and dehydration, contribute to the development of shock, with resultant multiorgan failure.
What type of shock is dengue shock?
Dengue Shock Syndrome (DSS) is defined as hypotension, narrow pulse pressure (£20 mm Hg), or frank shock in any case patient whose illness meets the criteria for DHF.
What are the challenges in developing a dengue vaccine?
Unlike other highly effective vaccines developed against other flaviviruses, the development of a dengue vaccine is highly challenging due to that fact that the virus has four antigenically different serotypes (DENV1–4).
How does the vaccine work dengue?
Dengvaxia contains weakened viruses that do not cause disease. When a person is given the vaccine, the immune system recognises the dengue proteins in the weakened viruses as ‘foreign’ and makes antibodies against them.
What is the shock?
Shock is a critical condition brought on by the sudden drop in blood flow through the body. Shock may result from trauma, heatstroke, blood loss, an allergic reaction, severe infection, poisoning, severe burns or other causes. When a person is in shock, his or her organs aren’t getting enough blood or oxygen.
What is the pathophysiology of dengue fever?
Pathophysiology Primary manifestations of disease include capillary leak syndrome (plasma leakage due to DHF-specific endothelial cell dysfunction), thrombocytopenia (seen in all types of DENV infection, but extreme in DHF), hemorrhagic tendencies, and leukopenia.
What is the current status of dengue vaccine development?
Currently, only one live attenuated chimeric dengue vaccine, the CYD Dengue Vaccine, has completed its third phase and has been licensed. DENVax and TetraVax-DV-TV003 (TV003) are in the third phase while others are still in the first trial phase.
WHO invented dengue vaccine?
A rare and severe form of dengue can be deadly, causing extensive bleeding under the skin and inside the body. Saint Louis University holds the patent on the vaccine, which was developed in 1997 by Thomas Chambers, M.D., then an associate professor of molecular microbiology and immunology.
What is the dengue vaccine made of?
Sanofi Pasteur’s Dengvaxia (CYD-TDV) is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes.
Which of the following is vaccine of dengue?
In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
What is the pathophysiology of shock?
Shock is an acute diffuse reduction in effective tissue perfusion that leads to an imbalance of oxygen supply and demand, anaerobic metabolism, cellular dysfunction, metabolic disarray, and eventually death.
What is shock pathology?
Shock is a life-threatening condition of circulatory failure, causing inadequate oxygen delivery to meet cellular metabolic needs and oxygen consumption requirements, producing cellular and tissue hypoxia.
What are the mechanism of shock?
Shock is a state of organ hypoperfusion with resultant cellular dysfunction and death. Mechanisms may involve decreased circulating volume, decreased cardiac output, and vasodilation, sometimes with shunting of blood to bypass capillary exchange beds.
What is the name of vaccine of dengue?
The Dengvaxia vaccine will be available starting in 2022 for use in children 9 through 16 years old with laboratory-confirmed evidence of a previous dengue virus infection and living in areas where dengue is common (occurs frequently or continuously).
What is Dengvaxia vaccine made of?
The Dengvaxia vaccine is a tetravalent, live-attenuated dengue vaccine. It was constructed using recombinant DNA technology and replaces several genetic sequences in a yellow fever vaccine virus genome with the homologous sequences from the four dengue virus serotypes, DENV-1–4.
Is there dengue vaccine?
Dengvaxia is approved for the prevention of dengue caused by all four dengue viruses. It is a live attenuated (weakened) virus vaccine. Who can get the dengue vaccine? It is approved for use in children 9–16 years old who have a previous history of laboratory-confirmed dengue infection.